Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis
Sarcoidosis
About this trial
This is an interventional diagnostic trial for Sarcoidosis
Eligibility Criteria
Inclusion Criteria:
- Individuals aged 18 or older
- Documentation of biopsy-proven sarcoidosis OR patients with typical findings on FDG PET and MRI without previous biopsy
- Clinical suspicion of cardiac involvement defined as the presence of any of the following: high-degree A-V nodal block, complete bundle branch block, reduced left or right ventricular systolic function, any cardiac arrhythmia, and/or unexplained chest pain, dyspnea or syncope
- PET/CT imaging demonstrating abnormal myocardial FDG uptake consistent with active inflammatory myocardium.
Exclusion Criteria:
- Initiation of steroids or any other immunosuppressive medication(s) following the completion of FDG-PET, as these medications, in theory, may subsequently suppress OctreoScan or DOTATATE uptake in the heart.
- Patients with history of neuroendocrine tumors (specially insulinomas)
- Patients taking the medication Octreotide
- Patients on total parenteral nutrition (TPN)
- Women who are pregnant or breastfeeding
Sites / Locations
- Brigham and Women's Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Indium-111 Pentreotide (OctreoScan)
Gallium-68 DOTATATE
Patients with biopsy-proven extra-cardiac sarcoidosis OR atypical findings on FDG PET and MRI without previous biopsy will be recruited to receive an injection of the FDA-approved radiotracer Indium-111 Pentreotide (OctreoScan). The imaging protocol will consist of imaging at 4 and 24 hours after OctreoScan injection.
Patients with biopsy-proven extra-cardiac sarcoidosis OR atypical findings on FDG PET and MRI without previous biopsy will be recruited to receive an injection of the FDA-approved radiotracer Gallium-68 DOTATATE. The imaging protocol will consist of imaging 1 hour after injection for DOTATATE.